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Antimicrobial peptides (AMPs) are ancient and conserved across the tree of life. Their efficacy over evolutionary time has been
largely attributed to their mechanisms of killing. Yet, the understanding of their pharmacodynamics both in vivo and in vitro is
very limited. This is, however, crucial for applications of AMPs as drugs and also informs the understanding of the action of
AMPs in natural immune systems. Here, we selected six different AMPs from different organisms to test their individual and
combined effects in vitro. We analyzed their pharmacodynamics based on the Hill function and evaluated the interaction of
combinations of two and three AMPs. Interactions of AMPs in our study were mostly synergistic, and three-AMP combinations
displayed stronger synergism than two-AMP combinations. This suggests synergism to be a common phenomenon in AMP in-
teraction. Additionally, AMPs displayed a sharp increase in killing within a narrow dose range, contrasting with those of antibi-
otics. We suggest that our results could lead a way toward better evaluation of AMP application in practice and shed some light
on the evolutionary consequences of antimicrobial peptide interactions within the immune system of organisms.
Combinations of drugs can result in three different forms ofinteractions: synergism, additivity, and antagonism (1–4);
i.e., the effect of two drugs combined is stronger, equal, and
weaker than that of the individual drug in the equivalent dose,
respectively. Combination treatment is supposed to potentially
eliminate resistant strains, delay the evolution of drug resistance,
reduce the dosage of individual drugs, and hence, diminish side
effects (3, 5, 6). A few recent studies, however, report that the
success of combination therapy is context dependent, particularly
when targeting both sensitive and resistant strains with a combi-
nation of drugs of unknown interaction (7–9). These results dem-
onstrated that synergistic drug pairs can efficiently eradicate bac-
teria but exacerbate selection of resistance, while antagonistic
drug pairs showed the reverse trends.
Various methods have been developed to address the efficacy
of mostly two-way drug combinations (1, 2). One of the most
commonly used approaches in both theoretical and applied re-
search is Loewe additivity (2, 9–11). Here, the effect of two drugs
in combination is determined by the sum of ratios of concentra-
tions of drugs in combination divided by concentration of drugs
used individually. Note that both the individual drug concentra-
tions and the combined concentrations have the same effect on
bacterial growth; we call these concentrations isoeffective concen-
trations. Theoretically, if the isoeffective concentrations of equiv-
alent effect level achieved in a matrix of gradients of concentra-
tions were connected by line, a concave line represents synergism,
while a convex line represents antagonism (2, 12, 13). Recently, a
mechanism-free approach was used successfully to predict the
outcome of three antibiotics on the interaction between all three
possible two-way combinations (14, 15), but the results do not
particularly address the question about the nature of interaction
(synergism, additivity, or antagonism). How these approaches can
be used for a new class of antimicrobials, antimicrobial peptides
(AMPs), is basically unknown. Studies on combinatorial effects of
antimicrobial peptides, especially within a pharmacodynamics
framework, are scarce (16, 17).
Antimicrobial peptides (AMPs), which form an important
component of immune defenses in multicellular organisms (18,
19), have been proposed and are being used as new antibiotic
drugs. Some AMPs are already commercially available and ready
to be applied in clinical practice to replace or accompany conven-
tional antibiotics (20). Additionally, they are supposed to be less
likely to induce resistance and mutagenesis in the natural environ-
ment, although resistant strains can be obtained under intensive
selection in the laboratory (21–23). When AMPs are used in med-
ical applications, they necessarily interact with the patient’s own
AMPs. Some experimental studies have addressed the effect of
individual pairs of AMPs within the context of innate immunity.
Coexpressed AMPs on frog skin, PGLa and magainin-2, are syn-
ergistic when applied to both Escherichia coli and tumor cells (16).
Moreover, AMPs from mammals (17) and insects (24, 25) were
shown to synergize. Hence, understanding general principles of
AMP interaction will also contribute to our understanding of in-
teractions of AMPs as immune effectors.
Here, we take a pharmacodynamic approach to study the com-
bination effects of AMPs and with combinations of two and three
AMPs. Pharmacodynamics capture the functional relationship
between drug dosage and bacterial growth or death. We use a
modeling approach based on the Hill function (26–28). This
model estimates four parameters: MIC, , min, and max (Fig.
1A). The minimal concentration at which antibiotic substances
can inhibit growth of bacteria is MIC;  depicts the steepness of
the curve relating bacterial growth to drug concentration (Fig.
1B);min andmax represent the minimum and maximum growth
rates of bacteria, respectively. We studied the pairwise and three-
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way interactions of AMPs using this pharmacodynamic approach
embedded in a Loewe additivity framework. According to the
work of Loewe, this was achieved by using either one-half (pair-
wise) or one-third (three-way) of the concentration of each indi-
vidual drug (see Materials and Methods) (10). We examined the
nature of the interactions, synergism or antagonism, and the con-
centration dependency of the killing. Using a derivative of the
human AMP LL-37 enabled us to study interactions between
AMPs expressed by patients’ innate immunity and AMPs em-
ployed as drugs.
MATERIALS AND METHODS
Bacteria andmedia. Escherichia coli MG1655 was grown in Luria-Bertani
(LB) broth at 37°C with aeration at 220 rpm in 50-ml tubes. Two hundred
microliters of overnight culture was resuspended into 15 ml fresh LB
broth, cultured under the same conditions for an additional 2 h, and then
used for subsequent assays. Mueller-Hinton (MH) broth was used for the
assay of MICs and time-killing curves.
AMPs and antibiotics. We used six different AMPs from different
classes of organisms that are commercially available (AnaSpec): cecropin
A (Cec) (insect), LL 19-27 (LL) (mammal), melittin (Mel) (insect), pexi-
ganan (Pex) (synthesized AMP, an analog of magainin II; a kind gift of
Michael Zasloff), indolicidin (Ind) (mammal), and apidaecin (Api) (in-
sect) (see Table S1 in the supplemental material). These AMPs are effec-
tive on either Gram-positive or Gram-negative bacteria (see reviews in
references 29 and 30). However, some of these AMPs, e.g., melittin and
pexiganan, have anticancer effects (16, 31, 32), which means that they are
potentially toxic to human cells, such as erythrocytes. Recently, some
low-cell-toxic and serum-stable AMPs have also been under development
(33, 34). All these AMPs were dissolved in distilled water with an initial
concentration of 1 mg/ml, 5 mg/ml, 10 mg/ml, 1 mg/ml, 1 mg/ml, and 25
mg/ml, respectively, as stock solutions. All antibiotics—ampicillin, cipro-
floxacin, gentamicin, kanamycin, neomycin, rifabutin, spectinomycin,
and tetracycline—were also dissolved in distilled water and made into
10-mg/ml stock solutions. All the solutions of AMPs and antibiotics were
stored at20°C in a dark environment.
MIC determination. According to a standard protocol (35), stock
solutions of AMPs were diluted in MH broth and then diluted in 96-well
plates with a 2-fold gradient, that is, from 0.25g/ml to 128g/ml. All the
gradients of antibiotics were from 0.02g/ml to 50g/ml, except that the
gradient of ciprofloxacin was from 0.002 g/ml to 1 g/ml. Approxi-
mately 5  105 log-phase bacteria were added to each well. A positive
control containing MH broth and bacteria and a negative control contain-
ing only MH broth were included in each plate, and plates were incubated
at 37°C overnight.
Measuring killing curves. To estimate killing curves of each AMP and
all possible combinations of AMPs, 100MICs of AMPs were combined
as a volume ratio of 1:1 and 1:1:1 in two-AMP combinations and three-
AMP combinations; hence, the concentrations of individual drugs are
halved or reduced by two-thirds. Thus, Loewe additivity would result in a
MIC of any one combination equal to the MIC of the individual drugs (see
equations 5 and 6). Thus, 21 two-AMP combinations and 20 three-AMP
combinations were generated. An AMP(s) was diluted, starting with 100
MIC, in a 96-well plate to form a 2-fold gradient of concentrations, and
2  106 log-phase bacteria were added to a total volume of 100 l. The
plates were incubated at 37°C. Killing was assessed within 1 h, as killing by
AMPs is very fast (36, 37). Ten microliters of a mixture of AMPs and
bacteria was taken out every 20 min and then immediately diluted in
saline solution and plated on the solid agar plates. These solid agar plates
were transferred into a 37°C incubator and cultured overnight for CFU
determination. The limit of detection in our system is 100 CFUs.
Modeling killing curves. To model the killing curve, the relationship
between the concentration of AMP(s) and the killing and/or growth rate
of exposed bacteria, we used a Hill function (26):
(a) Emax
a ⁄ EC50
1 a ⁄ EC50
(1)
Here, (a) is the killing rate at a given concentration of AMP(s); a is a
given concentration; Emax is the maximal killing rate of the given AMP(s).
 is the Hill coefficient. We then defined growth rate (a) as follows:
(a) max (a) (2)
Here, max is the maximal growth rate of bacteria without AMP(s). The
maximum effect of AMP(s) is defined by
Emax  max  min (3)
Thus, the effect of AMP(s) in a given concentration, (a), can be
rewritten as
FIG 1 Schematic illustration of four parameters, MIC, max, min, and , predicted by the Hill function. The MIC is estimated by the lowest concentration that
inhibits the growth of the whole treated bacterium population. max and min represent the maximal and minimal growth rates of bacteria under gradients of
drug treatment, respectively.  predicts the shape and slope of the pharmacodynamic curve; the higher the  value, the steeper the pharmacodynamic curve.
Yu et al.













max  min a ⁄ zMIC
a ⁄ zMIC  min ⁄ max
(4)
zMIC is the estimated MIC. Growth rate and killing rate of bacteria are
estimated from the time-kill curves as the change of CFU over time by
using generalized linear regression. The data for CFU were all log trans-
formed. The start point of linear regression was the first measurement. We
then fitted the growth rate and killing rate with equation 4 based on the
Markov chain Monte Carlo (MCMC) method using rjags (38) in R (39)
and generated the pharmacodynamic curves.
Determining the effect of combination. Based on the Hill function
and isobologram analysis, we obtained the isoeffective concentrations of
single drugs and of combinations which achieved a given percentage of
their maximal effects or fraction level. The Loewe additivity model defines
the additive effect of isoeffective combinations of drugs that result in a
certain effect. For example, the combination of drug A and drug B in the
isoeffective concentrations, which are CisoA and CisoB, can achieve a level
of effect which can also be achieved individually by drug A or drug B with
a concentration of CA or CB, respectively. Mathematically, the combina-



















Additive combination effects were then defined by a combination index
(CI) equal to 1, antagonism was defined as a CI greater than 1, and syn-
ergism was defined as a CI lower than 1.
RESULTS
Killing and pharmacodynamic curves. We tested the in vitro ef-
fects of single AMPs, two-AMP combinations, and three-AMP
combinations on E. coli. All killing curves were obtained by count-
ing viable CFU after treatment (see Fig. S1 in the supplemental
material). In most cases, the number of surviving bacteria drasti-
cally decreased as a function of time at higher concentrations
while slightly increasing at lower concentrations. Killing occurred
very quickly at higher concentrations in our system (i.e., bacterial
densities below the limit of detection).
The four pharmacodynamic parameters, MIC, , max, and
min, were estimated by the MCMC method using the generalized
linear regression fitted killing rate as a function of concentrations
of AMP(s) (Fig. 2 and 3; also see Table S2 in the supplemental
material). Notably, all the single AMPs and two- and three-AMP
combinations had almost the same min (analysis of variance
[ANOVA],min,F1,39 1.855,P 0.181) (Fig. 3; see also Table S2
in the supplemental material). max values were also identical in
different treatments as the growth rate of bacteria in low concen-
trations of AMP(s) was presumably close to the natural growth
rate. Two pharmacodynamic parameters, MIC and , varied
among different treatments, with three-AMP combinations
having the lowest MICs and the highest  values (ANOVA, MIC,
F1,39  6.647, P 0.0138; , F1,39  7.447, P 0.00935) (Fig. 3;
see also Table S2 in the supplemental material). All the treatments
showed nearly the same pharmacodynamic trend: a sharp de-
crease of net bacterial growth with an increasing concentration of
AMP(s) as depicted by .
Most AMP combinations are synergistic, but synergy is
stronger in three-AMP combinations. To determine the interac-
tion of AMPs, we used Loewe additivity (see equations 5 and 6).
The combination index was calculated for concentrations be-
tween 5% and 95% of the maximal effect (equation 3). For two-
AMP combinations, we found that most of the two-AMP combi-
nations (67%) were completely synergistic (combination indexes
were lower than 1) within the effect range, except for the combi-
nation of apidaecin and LL 19-27 (ApiLL), which was antagonistic
across the whole range; the combinations PexApi and IndApi were
antagonistic in low-concentration combinations but synergistic in
high-concentration combinations (Fig. 4; also see Fig. S2 in the
supplemental material). However, the combinations CecApi and
MelApi had a reverse trend, as they were synergistic in lower-
concentration combinations and antagonistic in higher-concen-
tration combinations (Fig. 4; see also Fig. S2 in the supplemental
material). Eighty-five percent of three-AMP combinations were
completely synergistic within the effect range while the combina-
tion LLPexApi was completely antagonistic; LLIndApi showed
synergistic effects in lower-concentration combinations and an-
tagonistic effects in higher-concentration combinations, but Me-
lIndApi had the reverse trend (Fig. 4; see also Fig. S2 in the sup-
plemental material).
Another interesting finding is that three-AMP combinations
generally have stronger effects than do two-AMP combinations at
a given fraction level within the effect range. The average combi-
nation indexes of three-AMP combinations were 30% lower than
those of two-AMP combinations (Student’s t test, t 8.2016, df
606.57, P  1.42e15) (Fig. 5). We observed no differences be-
tween effects of different fractions for the three-way interactions
(ANOVA, F1,661  1.332, P 0.2488) (Fig. 5).
Relationship between  values and selection. We compared
the  values of different combinations of AMPs and between
AMPs and antibiotics.  values are higher the more AMPs that are
combined. We also found that  values of AMPs are significantly
higher (ANOVA, F1,77  150.5, P 0.001) (Fig. 6) than those of
antibiotics, for data obtained in both our laboratory and other
laboratories (ANOVA, F1,36  1.591, P 0.215) (Fig. 6).
DISCUSSION
Pharmacodynamic approaches have been frequently applied to
conventional antibiotics (2, 11, 26, 40). A good understanding of
how antimicrobial peptides eradicate bacteria in complex systems
not only relies on the molecular mechanisms of killing but, im-
portantly, necessitates investigation of pharmacodynamics in
vitro, as done here and in vivo (C. Zanchi, P. R. Johnston, and J.
Rolff, unpublished data). Generally, the maximal killing values
were almost identical in treatments with all the AMPs and their
two- and three-way combinations, which means that high con-
centrations of an AMP(s) may eradicate bacteria with similar ef-
ficiencies. Due to fast killing of AMPs and the limit of detection in
our system, the real maximal killing rate might be masked at
higher concentrations, e.g., concentrations in which the limit of
detection is reached within 20 min. However, the MIC and  sig-
nificantly varied among single AMPs and two- and three-AMP
combinations. As numbers of AMPs increased in combination,
the MIC of that combination decreased, with the lowest value seen
in three-AMP combinations, and  was much higher in three-
AMP combinations (Fig. 3). More AMPs combined with lower
MICs demonstrate that the absolute quantity of AMP needs to be
decreased to achieve the same killing. Higher  values in com-
bined AMPs result in a drastic decrease in bacterial killing rate
within a narrow range of concentrations of the AMP(s). The com-
bination of AMPs might improve the efficiency of bacterial killing.
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Taken together, the decreasing MIC and increasing  values in
combinations with increasing numbers of AMPs suggest that syn-
ergism is common in AMP combinations (17, 24, 41).
We observed broad synergistic effects in almost all the two- and
three-way combinations. Although some AMPs, like apidaecin,
had a relatively weak effect with a high MIC, the killing could still
be enhanced by adding one or more AMPs with stronger individ-
ual effects. Synergism, albeit not within a pharmacodynamics
framework, has been reported for 2-way combinations of antibi-
otics (8, 42), AMPs (16, 17, 24), antimicrobial peptoids (43), an-
tibiotics and AMPs (44, 45), and AMPs and antimicrobial pep-
toids (43). The AMPs, originating from different species in our
experiment, showed robust synergism, which suggests a general
effect.
The molecular mechanisms of interaction, especially antago-
nisms, of AMPs are largely unknown. As most AMPs target the
FIG 2 Pharmacodynamic curves of AMPs. The pharmacodynamic curves of AMPs were obtained by fitting killing curves to the Hill function (see equation 4).
Combinations of two or three AMPs were differentiated. The curves illustrate the effects (reflected as net bacterial growth rate) of increasing the concentrations
of AMP(s). The ribbon represents the 95% confidence interval.
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membrane of pathogens, their interactions are unlikely to directly
disrupt the metabolic network in the cell like certain antibiotics. A
recent study suggested that synergism was caused by the conjuga-
tion of coapplied AMPs, which form a supermolecule and better-
stabilized pores (41). This is also confirmed by chemically con-
joined synthesized peptides (46). Furthermore, pore-forming
peptides can also assist other coapplied transmembrane AMPs to
quickly invade bacterial cells and substantially interrupt the me-
tabolism (47).
In our pharmacodynamic model, the important parameter 
depicts the steepness of the pharmacodynamic curve and is a mea-
sure of the sensitivity of the response of the bacteria to changes in
the concentrations of the antimicrobial substances. A steeper
pharmacodynamic curve with higher  values illustrates that bac-
teria are very sensitive to the change of concentrations of AMPs
and antibiotics, which means that the given antibiotic substance
(e.g., combinations of AMPs) has a narrower range of concentra-
tions exerting selection on bacteria.
Additionally,  value could be an important indicator of resis-
tance selection of given antibiotic agents. Traditionally, the pres-
ence of antimicrobial substances above the MIC is thought to
favor resistant strains. The mutant selection window (MSW) is
defined as the difference in the MICs of a resistant and a suscep-
tible strain (48, 49). Thus, the MSW can be specifically defined as
the range between the concentration killing all the sensitive strains
and the concentration killing all the resistant strains. Additionally,
MSW also can be defined as a range of concentrations which can
de novo select mutant strains from a completely sensitive popula-
tion (50–52). Higher  values in combinations of AMPs denote
a steeper pharmacodynamic curve, which means that the range
of concentrations selecting resistance—the MSW— can be nar-
rowed. Especially, the sub-MIC part of the MSW is predicted to be
very small for high  values. A previous theoretical study also
demonstrated that the synergistic contribution of the immune
system can potentially narrow the mutant selection window of
antibiotics (53). We observed a synergistic interaction in combi-
nations of AMPs that mirrors, in the case of LL 19-27, interactions
between the immune system and drugs. Higher  values of AMPs
than of antibiotics might partially explain the fact that bacteria are
unlikely to develop resistance to AMPs in nature, although resis-
tant strains can emerge under intensive selection in the laboratory
(21, 54).
Conclusion. Our study suggests that the synergistic effect be-
tween AMPs may be a common phenomenon, as we observed
strong synergistic interactions in two-AMP and three-AMP com-
binations. Interestingly, these three-AMP combinations are even
more synergistic than two-AMP combinations. If synergistic in-
teractions of AMPs are ubiquitous, than two practical implica-
tions arise: (i) AMPs that strongly synergize with host AMPs
should be utilized and (ii) combinations provide the opportunity
to reduce side effects, as they lead to an overall reduction in dos-
FIG3 Variations of MIC,, andmin in the Hill function predicted by the MCMC method. Results showed that these parameters vary among combinations with
different numbers of AMPs. MICs declined with increasing numbers of AMPs in combination (ANOVA, F1,39  6.647, P 0.0138); combinations with three
AMPs had the highest  values (ANOVA, F1,39  7.447, P  0.00935). min (Psimin) did not show significant differences among single AMPs and two- and
three-AMP combinations (ANOVA, F1,39  1.855, P 0.181).
FIG 4 Combination index of AMPs applied at concentrations which can
achieve 50% of their maximal effect (E50). At E50, all the combinations with Api
(except the combination of Api and Mel) showed antagonistic effects in two-
AMP combinations, but only two combinations, ApiIndMel and ApiLLPex,
showed antagonistic effects in three-AMP combinations. The gradient of col-
ors represents different levels of each interaction.
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age. In the context of innate immunity, selection should favor
organisms producing AMP cocktails. This can be considered a
cost-efficient way of reducing bacterial loads in a host (19, 55).
Long-lasting coexpression of combinations of AMPs has been
recorded in Xenopus laevis (56) and Tenebriomolitor (19), where it
is correlated with metabolic suppression. Thus, evolving a more
efficient killing system based on a relatively energy-constrained
system, which expresses only a limited number of AMPs, is nec-
essary and practical. A function of synergism among AMPs is one
of the possible ways to mitigate the costs.
Our results have some implications for the applied use of
AMPs as drugs. The production of AMPs is currently expensive
(20). The broad synergism observed in our experiment means that
combined applications of AMPs could also reduce the consump-
tion of total AMPs just as in the immune system, which could
eventually save costs of treatment and reduce toxicity. As humans
express AMPs such as LL-37 in their innate immune system, syn-
ergisms between these AMPs and AMPs applied as drugs should
be taken into account. In our study, the human AMP derivative LL
17-29 synergized with almost all combinations of AMPs. Though
resistance to single AMPs evolves readily in vitro, it is might be less
likely under combinations (54). It is possible that in some situa-
tions combinations delay the development of resistance in medi-
cal practice, as pathogens could pay a higher cost to evolve resis-
tance to multidrug treatment (57–60).
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